Citations (13)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Andrew Bivard, Neil Spratt, Christopher R Levi & Mark W Parsons. (2011) Acute stroke thrombolysis: time to dispense with the clock and move to tissue-based decision making?. Expert Review of Cardiovascular Therapy 9:4, pages 451-461.
Read now
Read now
Articles from other publishers (12)
Minghuan Jiang, Pengchao Li, Joyce Hoi-sze You, Xinglong Zheng, Jizhao Deng, Mingyue Zhao, Liuxin Feng & Yu Fang. (2019) Cost-effectiveness analysis of aspirin for primary prevention of cardiovascular events among patients with type 2 diabetes in China. PLOS ONE 14:12, pages e0224580.
Crossref
Crossref
Satoshi Kodera, Arihiro Kiyosue, Jiro Ando, Hiroshi Akazawa, Hiroyuki Morita, Masafumi Watanabe & Issei Komuro. (2017) Cost-Effectiveness Analysis of Cardiovascular Disease Treatment in Japan. International Heart Journal 58:6, pages 847-852.
Crossref
Crossref
Enrique Galve, Alberto Cordero, Vicente Bertomeu-Martínez, Lorenzo Fácila, Pilar Mazón, Eduardo Alegría, Jaime Fernández de Bobadilla, Esteban García-Porrero, Manuel Martínez-Sellés & José Ramón González-Juanatey. (2015) Novedades en cardiología: riesgo vascular y rehabilitación cardiaca. Revista Española de Cardiología 68:2, pages 136-143.
Crossref
Crossref
Enrique Galve, Alberto Cordero, Vicente Bertomeu-Martínez, Lorenzo Fácila, Pilar Mazón, Eduardo Alegría, Jaime Fernández de Bobadilla, Esteban García-Porrero, Manuel Martínez-Sellés & José Ramón González-Juanatey. (2015) Update in Cardiology: Vascular Risk and Cardiac Rehabilitation. Revista Española de Cardiología (English Edition) 68:2, pages 136-143.
Crossref
Crossref
Andrew Bivard, Peter Stanwell & Mark Parsons. 2014. Magnetic Resonance Spectroscopy. Magnetic Resonance Spectroscopy
183
195
.
N. L. de Groot, H. G. M. van Haalen, B. M. R. Spiegel, L. Laine, A. Lanas, J. Jaspers Focks, P. D. Siersema & M. G. H. van Oijen. (2013) Gastroprotection in Low-Dose Aspirin Users for Primary and Secondary Prevention of ACS: Results of a Cost-Effectiveness Analysis Including Compliance. Cardiovascular Drugs and Therapy 27:4, pages 341-357.
Crossref
Crossref
Zanfina Ademi, Danny Liew, Bruce Hollingsworth, Ph.Gabriel Steg, Deepak L. Bhatt & Christopher M. Reid. (2011) Is It Cost‐Effective To Increase Aspirin Use in Outpatient Settings for Primary or Secondary Prevention? Simulation Data from the REACH Registry Australian Cohort. Cardiovascular Therapeutics 31:1, pages 45-52.
Crossref
Crossref
Mark F. McCarty. (2013) Dietary nitrate and reductive polyphenols may potentiate the vascular benefit and alleviate the ulcerative risk of low-dose aspirin. Medical Hypotheses 80:2, pages 186-190.
Crossref
Crossref
Peter C Elwood, Mohammed Mustafa, Maribel Almonte & Gareth Morgan. (2012) The risks and benefits of prophylactic aspirin in vascular disease and cancer. Clinical Investigation 2:12, pages 1177-1184.
Crossref
Crossref
Martina Mylrea, Sherryl Robertson, Alison Haywood & Beverley Glass. (2012) Stability of Dispersible Aspirin Tablets Repacked into Dosette Boxes. Journal of Pharmacy Practice and Research 42:3, pages 204-207.
Crossref
Crossref
M. Brandon Westover, Nathaniel A. Eiseman & Matt T. Bianchi. (2012) Should risky treatments be reserved for secondary prevention? Theoretical considerations regarding risk–benefit tradeoffs. Journal of Clinical Epidemiology 65:8, pages 877-886.
Crossref
Crossref
Peter M Rothwell, F Gerald R Fowkes, Jill FF Belch, Hisao Ogawa, Charles P Warlow & Tom W Meade. (2011) Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. The Lancet 377:9759, pages 31-41.
Crossref
Crossref